SCHEMBL10219841

SCHEMBL10219841

CCOC(=O)c1cccc(OC2CCN(c3nc4ccc(Cl)cc4s3)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 2/20 0.56
PPARG P37231 5/20 0.52
PPARD Q03181 5/20 0.52
PPARA Q07869 4/20 0.52
NPC1 O15118 4/20 0.50
RAB9A P51151 3/20 0.50
ALDH1A1 P00352 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
KDM4E B2RXH2 2/20 0.49
CYP2D6 P10635 1/20 0.49
HPGD P15428 1/20 0.49
TP53 P04637 4/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
GAA P10253 2/20 0.47
TSHR P16473 1/20 0.47
MGLL Q99685 1/20 0.46
HCRTR1 O43613 1/20 0.46
HCRTR2 O43614 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10219848 0.88 PPARG (0.59) PCSK9PPARGPPARDPPARANPC1
SCHEMBL10220125 0.87 PPARG (0.56) PPARGPPARDPPARANPC1RAB9A
SCHEMBL334267 0.87 PPARG (0.70) PCSK9PPARGPPARDPPARANPC1
SCHEMBL10219838 0.86 PPARD (0.61) PPARGPPARDPPARANPC1RAB9A
SCHEMBL10219880 0.83 PPARD (0.59) PCSK9PPARGPPARDPPARANPC1
SCHEMBL10220127 0.81 PPARD (0.75) PPARGPPARDPPARACYP2C9
SCHEMBL10219914 0.80 PPARG (0.61) PCSK9PPARGPPARDPPARANPC1
SCHEMBL10219877 0.80 PPARG (0.57) PCSK9PPARGPPARDPPARANPC1
SCHEMBL10219861 0.79 PPARG (0.69) PCSK9PPARGPPARDPPARANPC1
SCHEMBL10219920 0.77 PPARG (0.57) PCSK9PPARGPPARDPPARANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG PCSK9 1075/4885PPARG 3/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.